We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
- Authors
Reni, Michele; Cereda, Stefano; Rognone, Alessia; Belli, Carmen; Ghidini, Michele; Longoni, Simonetta; Fugazza, Clara; Rezzonico, Sara; Passoni, Paolo; Slim, Najla; Balzano, Giampaolo; Nicoletti, Roberto; Cappio, Stefano; Doglioni, Claudio; Villa, Eugenio
- Abstract
PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine. The current trial was aimed at assessing whether the replacement of E with docetaxel (D) may improve 6 months PFS (PFS6).
- Publication
Cancer chemotherapy and pharmacology, 2012, Vol 69, Issue 1, p115
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-011-1680-2